IL111843A - Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation - Google Patents

Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation

Info

Publication number
IL111843A
IL111843A IL11184394A IL11184394A IL111843A IL 111843 A IL111843 A IL 111843A IL 11184394 A IL11184394 A IL 11184394A IL 11184394 A IL11184394 A IL 11184394A IL 111843 A IL111843 A IL 111843A
Authority
IL
Israel
Prior art keywords
phenylprop
crystalline
processes
preparation
carboxylic acid
Prior art date
Application number
IL11184394A
Other languages
English (en)
Other versions
IL111843A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL111843A0 publication Critical patent/IL111843A0/xx
Publication of IL111843A publication Critical patent/IL111843A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11184394A 1993-12-08 1994-12-01 Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation IL111843A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (2)

Publication Number Publication Date
IL111843A0 IL111843A0 (en) 1995-03-15
IL111843A true IL111843A (en) 2000-02-29

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11184394A IL111843A (en) 1993-12-08 1994-12-01 Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation

Country Status (31)

Country Link
US (1) US5434171A (de)
EP (3) EP0657428B1 (de)
JP (2) JP3834075B2 (de)
KR (1) KR100356239B1 (de)
CN (2) CN1057294C (de)
AT (1) ATE200279T1 (de)
AU (1) AU681198B2 (de)
BR (1) BR9404842A (de)
CA (1) CA2137221C (de)
CO (1) CO4290427A1 (de)
CZ (1) CZ290559B6 (de)
DE (1) DE69427017T2 (de)
DK (1) DK0657428T3 (de)
ES (1) ES2155844T3 (de)
FI (2) FI106455B (de)
GR (1) GR3036136T3 (de)
HK (1) HK1013826A1 (de)
HU (1) HUT71489A (de)
IL (1) IL111843A (de)
MY (1) MY121543A (de)
NO (1) NO302884B1 (de)
NZ (1) NZ270039A (de)
PE (1) PE41495A1 (de)
PL (1) PL181734B1 (de)
PT (1) PT657428E (de)
RU (1) RU2145958C1 (de)
SI (1) SI0657428T1 (de)
TW (1) TW290540B (de)
UA (1) UA52577C2 (de)
YU (2) YU49312B (de)
ZA (1) ZA949584B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU2002314967B2 (en) * 2001-06-05 2007-09-20 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
RU2362560C2 (ru) 2003-04-08 2009-07-27 Проджиникс Фармасьютикалз, Инк. Фармацевтическая препаративная форма
AU2004229462A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
NZ548529A (en) 2003-12-16 2010-08-27 Nektar Therapeutics Pegylated small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
SI1789067T1 (sl) * 2004-08-12 2012-09-28 Helsinn Healthcare Sa Uporaba spojine rastnega hormona sekretagoga za stimulacijo dejavnosti gastrointestinalnega sistema
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CA2616918A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
US20090325857A1 (en) 2006-04-21 2009-12-31 Raphael Beumer Use of opioid receptor antagonists
JP2010510329A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド 7,8−飽和−4,5−エポキシ−モルフィナニウム類似体
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
CA2682550C (en) 2007-03-29 2016-05-17 Wyeth Peripheral opioid receptor antagonists and uses thereof
US20100305323A1 (en) 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
ME03468B (de) 2009-12-04 2020-01-20 Alkermes Pharma Ireland Ltd Morphinanderivate zur behandlung einer drogenüberdosis
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス, インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
ZA922180B (en) * 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives

Also Published As

Publication number Publication date
FI945703A (fi) 1995-06-09
CA2137221A1 (en) 1995-06-09
FI20000353A (fi) 2000-02-17
EP0984004A3 (de) 2003-10-15
EP0984004A2 (de) 2000-03-08
YU70294A (sh) 1997-07-31
ES2155844T3 (es) 2001-06-01
AU681198B2 (en) 1997-08-21
CN1121387C (zh) 2003-09-17
JP2006070042A (ja) 2006-03-16
KR950017957A (ko) 1995-07-22
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
PL306068A1 (en) 1995-06-12
US5434171A (en) 1995-07-18
ZA949584B (en) 1996-06-03
YU49312B (sh) 2005-06-10
JP3834075B2 (ja) 2006-10-18
NO944644L (no) 1995-06-09
IL111843A0 (en) 1995-03-15
EP1607387A2 (de) 2005-12-21
CA2137221C (en) 2011-02-22
DE69427017T2 (de) 2001-09-06
AU7917094A (en) 1995-06-15
KR100356239B1 (ko) 2002-12-26
PT657428E (pt) 2001-07-31
BR9404842A (pt) 1995-08-08
UA52577C2 (uk) 2003-01-15
SI0657428T1 (en) 2001-08-31
EP0657428A1 (de) 1995-06-14
YU82304A (sh) 2006-03-03
NO302884B1 (no) 1998-05-04
PE41495A1 (es) 1995-11-28
EP0657428B1 (de) 2001-04-04
JPH07215937A (ja) 1995-08-15
CN1111239A (zh) 1995-11-08
CN1223257A (zh) 1999-07-21
TW290540B (de) 1996-11-11
CN1057294C (zh) 2000-10-11
RU94042903A (ru) 1996-10-27
MY121543A (en) 2006-02-28
NO944644D0 (no) 1994-12-02
DE69427017D1 (de) 2001-05-10
PL181734B1 (pl) 2001-09-28
ATE200279T1 (de) 2001-04-15
CO4290427A1 (es) 1996-04-17
HK1013826A1 (en) 1999-09-10
CZ299294A3 (en) 1995-10-18
DK0657428T3 (da) 2001-05-07
GR3036136T3 (en) 2001-09-28
FI106455B (fi) 2001-02-15
EP1607387A3 (de) 2007-01-03
HUT71489A (en) 1995-11-28
CZ290559B6 (cs) 2002-08-14
RU2145958C1 (ru) 2000-02-27
NZ270039A (en) 1996-08-27
FI945703A0 (fi) 1994-12-02

Similar Documents

Publication Publication Date Title
IL111843A (en) Crystalline 3,4,4-trisubstituted piperidinyl-N-(3-phenylprop-2-YL) carboxylic acid derivatives pharmaceutical compositions containing them and processes for their preparation
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
HUT52070A (en) Herbicide compositions containing pyrimidinyl-benzoic acid derivatives as active components, and process for producing the active components
AU1331588A (en) Method for treatment of alcohol abuse
CA2119853A1 (fr) Nouvelles pyridothiadiazines, leurs procedes de preparation, et les compositions pharmaceutiques qui les contiennent
CA2263563A1 (en) Cyclopentenones, process for preparing the same, and the use thereof
PL295331A1 (en) Method of obtaining novel derivatives of quinolonocarboxylic acid
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
HUT50790A (en) Process for producing new 3,5-dihydroxycarboxylic acids and derivatives thereof, as well as pharmaceutical compositions and intermediates comprising such compounds
HUT47793A (en) Herbicide compositions containing 2,6-substituted-pyridine-carboxylic acid derivatives as active components and process for producing the active components
CS235488A2 (en) Method of new dihydropyridinamides production
HUT41984A (en) Process for producing pharmaceutical compositions containing 9,10-dihydro-ergot-alkaloides
EP0521393A3 (en) Diclofenac salt, a method for the preparation thereof and pharmaceutical compositions containing it
IL81831A0 (en) Method and compositions for controlling weeds containing 1-methyl-1h-imidazole-5-carboxylic acid derivatives,certain such novel compounds and their preparation
HUT53643A (en) Process for producing substituted azetidinye-pyridon-carboxylic acid derivatives and pharmaceutical compositions containing them
HUT47792A (en) Herbicide compositions containing 2,6-substituted-pyridine-carboxylic acid derivatives as active components and process for producing the active components
SG52396A1 (en) Process for preparing purified 2,6-naphtalenedicorboxylic acid
KR960015807B1 (en) Process for the preparation of purified bis(2-hydrozyethyl) ester of 2,60naphthalenedi carboxylic acid
GR3020230T3 (en) Acylsulphonamido and sulphonamidopyridine-2-carboxylic acid esters, pyridine-n-oxides thereof, a process for their preparation and their use as medicaments
HUT48898A (en) Process for producing intermediate compounds for producing herbicide compositions containing amino-methylene-phosphonic acid derivatives
HUT48461A (en) Process for producing pharmaceutical compositions containing 1,4-dihydropyridine derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
FF Patent granted
KB Patent renewed
EXP Patent expired